Celldex Therapeutics has halted work on its solid-tumor-focused bispecific as the biotech prioritizes its work in ...

Study findings suggest the potential to repurpose a drug that is FDA-approved for treating asthma and eczema, to enhance ...

The first patient has been treated in a phase 1/2 clinical trial of an experimental Moderna vaccine designed to generate antibodies against PD-L1 and IDO1 – two targets thought to protect ...

We determine the molecular mechanisms involved in the regulation of gene expression and signal transduction pathways in drug resistance ... Our preliminary data revealed that PD-1, an immune ...

Dr Judy Chou, CEO, President and Board Member of AltruBio, Inc, explains how agonist antibodies show potential as a novel therapeutic approach in immunological diseases.

Welcome to the Merck & Company Q3 sales and earnings conference call. [Operator instructions] This call is being recorded.

Lyell Immunopharma, Inc.'s strong financials, innovative CAR T-cell therapies, and strategic acquisitions position it for ...

rather than to defects in proximal insulin signaling. Consequently, elucidating the metabolic pathways associated with the GLUT4 transporter represents a promising avenue for discovering new ...

During the last few years there have been significant developments in the control of highly uncertain, nonlinear dynamical systems. For systems with parametric uncertainty, adaptive nonlinear control ...

Monte Rosa Therapeutics, Inc. secures $150M partnership with Novartis for immune treatments. Click for my updated look at ...